Zanzalintinib is a selective inhibitor of the c-Met receptor tyrosine kinase, a potent anticancer agent currently studied for its efficacy in treating non-small cell lung cancer and other solid tumors… Read more
Zanzalintinib is a selective inhibitor of the c-Met receptor tyrosine kinase, a potent anticancer agent currently studied for its efficacy in treating non-small cell lung cancer and other solid tumors characterized by MET pathway overexpression. This category provides access to high-quality reference standards of the parent drug, alongside stable isotope labelled compounds such as Zanzalintinib-d3 and Zanzalintinib-d6. Pharmaceutical laboratories and researchers utilize these compounds to conduct precise impurity profiling, method validation, and rigorous quality control. By serving as internal standards in bioanalytical assays, these labelled analogues enable accurate quantitation of the parent drug in complex matrices, supporting the development of reliable analytical protocols essential for therapeutic drug monitoring and pharmacokinetic studies in oncology research.